neutrophilic leukemia

Also found in: Encyclopedia.

neu·tro·phil·ic leu·ke·mi·a

an unusual form of chronic granulocytic leukemia in which the greatly increased number of leukocytes in the circulating blood are mature polymorphonuclear neutrophils, with virtually no young or immature granulocytes being observed.
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
Gotlib J, Maxson JE, George TI and Tyner JW The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013; 27: 1870-1873, doi: 10.1038/leu.2013.122.
Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management.
(13) (1/145) (19/113) aCML: atypical chronic myeloid leukemia; CMML: chronic myelomonocytic leukemia; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; MDS-MPN, U: myelodysplastic-myeloproliferative neoplasm, unclassifiable; JMML: juvenile myelomono-cytic leukemia; PMF: primary myelofibrosis; CNL: chronic neutrophilic leukemia; AML: acute myeloid leukemia; sAML: secondary acute myeloid leukemia; ND: no data.
Chronic neutrophilic leukemia (CNL) is a rare and fatal myeloproliferative disease, first described by Tuohy in 1920.[30] No more than 70 cases have been reported.
An association between chronic neutrophilic leukemia and multiple myeloma with a study of cobalamin-binding proteins.
Cytobiologic and clinical aspects in a patient with chronic neutrophilic leukemia after thorotrast exposure.
Chronic neutrophilic leukemia associated with polycythemia vera.
Cervantes F, Rozman M, Vives-Corrons J-L, et al: Chronic neutrophilic leukemia with dysplastic features.
The MPN category includes chronic myelogenous leukemia, PV, ET, PMF, chronic neutrophilic leukemia, mastocytosis, and others.
As for the less common MPNs, mutations in the receptor for colony-stimulating factor 3 (CSF3R), initially identified in patients with severe congenital neutropenia, (68-70) have been described in 59% of patients with chronic neutrophilic leukemia or atypical chronic myelogenous leukemia.